

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)



(10) International Publication Number

WO 2022/200457 A1

(51) International Patent Classification:
C12Q 1/6886 (2018.01)

(21) International Application Number:
PCT/EP2022/057673

(22) International Filing Date:
23 March 2022 (23.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21164371.3 23 March 2021 (23.03.2021) EP

(71) Applicants: **DEUTSCHES KREBS-
FORSCHUNGSZENTRUM STIFTUNG DES ÖF-
FENTLICHEN RECHTS** [DE/DE]; Im Neuenheimer
Feld 280, 69120 Heidelberg (DE). **UNIVERSITÄT
HEIDELBERG** [DE/DE]; Grabengasse 1, 69117 Heidel-
berg (DE).

(72) Inventors: **OFFRINGA, Rienk**; Deutsches Krebs-
forschungszentrum, Innovations-Management, T010, Im
Neuenheimer Feld 280, 69120 Heidelberg (DE). **MENG, Zibo**; Deutsches Krebsforschungszentrum, In-
novations-Management, T010, Im Neuenheimer Feld
280, 69120 Heidelberg (DE). **RODRIGUEZ EHREN-
FRIED, Aaron**; Deutsches Krebsforschungszentrum, In-
novations-Management, T010, Im Neuenheimer Feld 280,
69120 Heidelberg (DE). **STEFFENS, Laura Katharina**;
Deutsches Krebsforschungszentrum, Innovations-Management,
T010, Im Neuenheimer Feld 280, 69120 Heidelberg
(DE). **TAN, Chin Leng**; Deutsches Krebsforschungszentrum,
Innovations-Management, T010, Im Neuenheimer
Feld 280, 69120 Heidelberg (DE).

(74) Agent: **ALTMANN STÖSSEL DICK PATENTAN-
WÄLTE PARTG MBB**; Dr. Alexander Dick, Theodor-
Heuss-Anlage 2, 68165 Mannheim (DE).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2022/200457 A1

(54) Title: ANTIGEN REACTIVE T-CELL RECEPTORS

(57) Abstract: The present invention relates to a method of identifying a T-cell reactive to cells presenting a T-cell activating antigen (cancer-reactive T-cell), comprising (a) determining expression of at least one of CCL4, CCL4L2, CCL3, CCL3L1, and CXCL13 in T-cells from a sample of a subject; and (b) identifying a cancer-reactive T-cell based on the determination of step (a). The present invention also relates to a method of identifying a TCR binding to a cancer cell of a subject, said method comprising (A) identifying a cancer reactive T-cell according to the afore-said method (B) providing the amino acid sequences of at least the complementarity determining regions (CDRs) of the TCR of the cancer-reactive T-cell identified in step (A); and, hereby, (C) identifying a TCR binding to a cancer cell. The present invention further relates to further methods and cancer-reactive T-cells related thereto.